# IMvigor010 (NCT02450331)

> A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02450331
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Transitional Cell
- Interventions: Atezolizumab
- Enrollment: 809
- Primary outcome: Disease-Free Survival (DFS), as Assessed by Investigator

## Commentary we found

- X threads: 57
- YouTube: 38
- Podcasts: 30

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imvigor010-nct02450331

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02450331", "email": "<work email>"}; the inbox owner confirms by the emailed link.